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Abstract Recent studies have shown that, in addition to its role
as an adhesion receptor, platelet endothelial cell adhesion
molecule 1/CD31 becomes phosphorylated on tyrosine residues
Y663 and Y686 and associates with protein tyrosine phosphatases
SHP-1 and SHP-2. In this study, we screened for additional
proteins which associate with phosphorylated platelet endothelial
cell adhesion molecule 1, using surface plasmon resonance. We
found that, besides SHP-1 and SHP-2, platelet endothelial
cell adhesion molecule 1 binds the cytoplasmic signalling
proteins SHIP and PLC-Q1 via their Src homology 2 domains.
Using two phosphopeptides, NSDVQpY663TEVQV and
DTETVpY686SEVRK, we demonstrate differential binding of
SHP-1, SHP-2, SHIP and PLC-Q1. All four cytoplasmic
signalling proteins directly associate with cellular platelet
endothelial cell adhesion molecule 1, immunoprecipitated from
pervanadate-stimulated THP-1 cells. These results suggest that
overlapping immunoreceptor tyrosine-based inhibition motif/
immunoreceptor tyrosine-based activation motif-like motifs
within platelet endothelial cell adhesion molecule 1 mediate
differential interactions between the Src homology 2 containing
signalling proteins SHP-1, SHP-2, SHIP and PLC-Q1.
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1. Introduction
Platelet endothelial cell adhesion molecule 1 (PECAM-1)
(CD31) is a 130 kD glycoprotein that mediates adhesive in-
teractions between vascular cells. While its role as a homo-
philic adhesion receptor is well-established, recent studies have
shown that PECAM-1 engagement is able to transmit signals
into cells leading to a diverse range of functional outcomes [1].
The cytoplasmic domain of PECAM-1 is unusual for an ad-
hesion receptor as it contains a long cytoplasmic tail (118
amino acids) derived from seven separate exons [2]. There is
now increasing evidence that the phosphorylation of two tan-
dem tyrosine residues (Y663 and Y686) within the cytoplasmic
domain of PECAM-1 is required for the downstream signal-
ling events observed following PECAM-1 ligation [3^12].
Although the cytoplasmic domain of PECAM-1 contains no
intrinsic kinase or phosphatase activity, members of the Src-
and Csk-related protein tyrosine kinases (PTKs) are able to
phosphorylate Y663 and Y686 [3,8,9]. When phosphorylated,
these residues are responsible for the recruitment and activa-
tion of the Src homology 2 (SH2) containing protein tyrosine
phosphatases SHP-1 and SHP-2 [3^7,11].
The amino acid residues surrounding PECAM-1 tyrosine
residues Y663 and Y686 appear to conform to the consensus
sequences for both immunoreceptor tyrosine-based activation
motifs (ITAMs) and immunoreceptor tyrosine-based inhibi-
tion motifs (ITIMs) [4,5,9]. The demonstration that phospho-
peptides containing tyrosine residues pY663 and pY686 can
associate with and activate SHP-1 and SHP-2, suggests that
these ITIM-like sequences are functionally important. On the
other hand, the engagement of PECAM-1 on T lymphocytes
results in proliferation, secretion of several chemokines/cyto-
kines and up-regulation of CD25 in response to sub-optimal
concentrations of anti-CD3 antibodies: all characteristic hall-
marks of co-stimulatory, ITAM containing receptors [13]. The
co-precipitation of several phosphorylated proteins that asso-
ciate with PECAM-1 suggests that PECAM-1 is likely to reg-
ulate intracellular signalling as part of a complex of signalling
proteins [4,9].
In this study, we have used surface plasmon resonance to
screen a panel of SH2 domains from cytoplasmic signalling
proteins, known to become tyrosine-phosphorylated upon cell
activation, for their ability to bind a glutathione-S-transferase
(GST)-PECAM-1 cytoplasmic domain fusion protein. In ad-
dition to SHP-1 and SHP-2, we have found that SHIP and
PLC-Q1 can interact speci¢cally with the phosphorylated cy-
toplasmic PECAM-1 domain. Mapping studies have shown
that the SH2 domains of SHP-1, SHP-2, SHIP and PLC-Q1
interact di¡erentially with pY663 and pY686 in PECAM-1. Our
results suggest that the cytoplasmic domain of PECAM-1
contains overlapping ITIM/ITAM-like motifs which di¡eren-
tially associate with the SH2 containing signalling proteins
SHP-1, SHP-2, SHIP and PLC-Q1.
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2. Materials and methods
2.1. Peptides and antibodies
All reagents were purchased from Sigma unless otherwise stated.
Anti-phosphotyrosine antibody 4G10 was purchased from Upstate
Biotechnology. Biotinylated peptides (NSDVQpY663TEVQV and
DTETVpY686SEVRK) were purchased from Alta Bioscience (Bir-
mingham UK), were HPLC-puri¢ed and judged s 90% pure by
mass spectroscopy.
2.2. GST fusion proteins
GST fusion proteins of PLC-Q1, Shc, PI-3 kinase (p85), SHIP and
Grb2 were purchased from Santa Cruz (CA, USA). Individual SH2
domains from SHP-1 and SHP-2 and mutant PECAM-1 cytoplasmic
domains were produced and puri¢ed using Bulk GST puri¢cation
modules (Pharmacia Biotech, UK) according to the manufacturer‘s
instructions. The fusion proteins used in this study are shown in
Fig. 1.
2.3. PECAM-1, SHP-1 and SHP-2 GST constructs
The cDNAs for PECAM-1 Y663F, Y686F and Y663/686F con-
structs in pcDNA3 were kindly provided by Dr. Peter Newman
(Blood Research Institute, Milwaukee, WI, USA). Ampli¢ed products
were cloned into pGEX-4T (Amersham-Pharmacia) using BamHI and
SalI sites. The SH2 domains of SHP-1 and SHP-2 were generated by
PCR ampli¢cation from SHP-1 and SHP-2 cDNA (kindly provided
by Dr. Benjamin Neel, Beth Israel Hospital, Boston, MA, USA).
Ampli¢ed products were cloned into pGEX-4T (Amersham-Pharma-
cia). All cDNAs were sequenced to exclude PCR-induced errors.
Primer sequences are available on request.
2.4. In vitro c-Src kinase phosphorylation of PECAM-1 GST proteins
GST-PECAM-1 fusion proteins or GST alone (Santa Cruz) were
phosphorylated in vitro by incubating 100 Wg samples with 18.5 U of
c-Src kinase (Upstate biotechnology) in 500 Wl kinase bu¡er (50 mM
HEPES pH 7.4, 50 mM NaCl, 0.1 mM Na3VO4, 5 mM MgCl2, 5 mM
MnCl2 and 5 mM ATP) for 2 h at 20‡C. To assess GST fusion
proteins in the absence of phosphorylation, ATP and divalent cations
were replaced with 10 mM EDTA.
2.5. Surface plasmon resonance
Measurements were carried out on a BIAcore 2000 Biosensor (BIA-
core AB, Uppsala, Sweden). GST fusion proteins (W1000 response
units (RU)) were immobilised directly onto a CM5 BIAcore sensor
chip using the recommended protocol. Biotinylated PECAM-1 phos-
phopeptides (W200 RU) were immobilised to streptavidin-coated
BIAcore SA biosensor chips using the recommended protocol. In
both cases, the presence of accessible phosphotyrosine residues was
con¢rmed using the anti-phosphotyrosine monoclonal antibody 4G10
(data not shown). Data were acquired using the Kinject function of
the BIAcore, each injection lasting 120 s with a dissociation period of
200 s and a £ow rate of 10 Wl/min. The response (RU) relative to the
pre-injection of analyte was measured 60 s after the end of the in-
jection. Binding to unphosphorylated GST-PECAM-1 was sub-
tracted from phosphorylated GST-PECAM-1 and unphosphorylated
GST from phosphorylated GST and in all cases was less than 50
RU.
2.6. Immunoprecipitation analysis
Control and stimulated THP-1 cells (typically 107) were lysed in
20mM Tris-HCl, pH8, 150 mM NaCl, 1% Triton X-100, 1 mM
Na3VO4, 1 mM AEBSF and 10 mg/ml leupeptin for 20 min at 4‡C.
Pre-cleared cell lysates were incubated with 2Wg anti-PECAM-1 anti-
body (9G11) or mouse IgG1 control for 1 h and then immunopre-
cipitated with protein G-sepharose overnight. After three washes with
ice-cold lysis bu¡er, bound proteins were eluted from the sepharose
beads by boiling in SDS reducing bu¡er, resolved on 10% SDS-
PAGE, transferred to Hybond-P membranes and probed with the
relevant antibodies or GST-SH2 domains. Detection was done with
HRP-conjugated secondary antibodies using chemiluminescence. Far
Western blots were probed with 2 Wg of GST fusion protein for 1 h at
room temperature. Bound GST proteins were detected using a goat
anti-GST polyclonal antibody followed by HRP-conjugated anti-goat
antibody.
3. Results
3.1. PECAM-1 interacts with the cytoplasmic signalling
proteins SHP-1, SHP-2, PLC-Q1 and SHIP via their SH2
domains
Previous studies have suggested that in addition to SHP-1
and SHP-2, PECAM-1 can potentially associate with at least
three other phosphotyrosine containing proteins [4,8,9]. We
therefore screened a panel of SH2 containing signalling pro-
teins for their ability to interact with GST-PECAM-1 in a
phosphotyrosine-dependent manner. To validate our screen-
ing protocol and con¢rm that the immobilisation of phos-
phorylated GST-PECAM-1 fusion protein to the BIAcore
sensor chip did not a¡ect the functional ability of PECAM-
1 to interact with SH2 domains, we examined the ability of
two SH2 containing proteins, SHP-1 and SHP-2, known to
interact with PECAM-1. These positive controls bound well
to PECAM-1, as did two other signalling proteins, PLC-Q1
and SHIP (Fig. 2). These interactions were speci¢c, titratable
over the range 25^400 nM and relied entirely on pY663 and
pY686 within the cytoplasmic domain of PECAM-1, since
there was no signi¢cant binding to unphosphorylated PE-
CAM-1 or a Y663/686F mutant (data not shown). There
was no binding of p85 PI-3 kinase, Grb2, Shc or GST to
PECAM-1 at any of the concentrations used.
We next examined the relative contribution of individual
NH2- and COOH-terminal (NC) SH domains within SHP-1,
SHP-2 and PLC-Q1 to the interaction with PECAM-1 (Fig. 3).
As expected, SH3-PLC-Q1 was unable to bind the phosphoryl-
ated PECAM-1 cytoplasmic domain. NC-PLC-Q1 fusion pro-
tein, containing the two SH2 domains in tandem, bound GST-
PECAM-1 as e¡ectively as the NC-SH3-PLC-Q1 fusion pro-
tein, con¢rming that the SH3 domain plays no part in the
interaction of PLC-Q1 with PECAM-1. Unlike PLC-Q1 in
which both the NH2 (N) and COOH-terminal (C) SH2 do-
mains were able to bind PECAM-1, both SH2 domains were
required for signi¢cant binding of SHP-1 to PECAM-1. Only
the N-SH2 domain of SHP-2 was able to interact with PE-
CAM-1. In all three cases, the presence of both SH2 domains
in tandem led to a signi¢cantly enhanced binding compared to
either SH2 domain on their own (Fig. 3).
Fig. 1. GST fusion proteins used in this study. Listed are the vari-
ous GST fusion proteins used in this study. Proteins start with the
N-SH2 domains at the left.
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3.2. Di¡erential interaction of the SH2 domains of SHP-1,
SHP-2, SHIP and PLC-Q1 with either PECAM-1 pY663 or
pY686
In order to determine which of the two phosphotyrosine
motifs the individual SH2 domains were binding, we used a
pair of biotinylated 11 amino acid phosphopeptides,
NSDVQpY663TEVQV and DTETVpY686SEVRK. We were
unable to use GST-PECAM-1 proteins containing mutations
at Y663 and Y686 as these proteins were not fully phosphoryl-
ated by c-Src (data not shown). While NC-SHP-2 interacted
predominantly with the pY663 containing phosphopeptide,
SHIP interacted predominantly with the pY686 containing
peptide. NC-SHP-1 was unable to bind either phosphopeptide
(Fig. 4A). In contrast, NC-PLC-Q1 bound both phosphopep-
tides although the interaction was greater with pY663 than
pY686 (Fig. 4B). These results suggest that the SH2 domains
of these four signalling proteins interact di¡erentially with the
two PECAM-1 tyrosine motifs. They also con¢rm that both
phosphopeptides are functionally active when immobilised to
the BIAcore chip.
Since SHIP contains a single SH2 domain, we were able to
directly map the dominant binding site on PECAM-1 to pY686
Fig. 3. Interaction of individual NC-SH2 domains from SHP-1, SHP-2 and PLC-Q1 with GST-PECAM-1. BIAcore sensor chip was immobilised
with in vitro kinase-treated GST-PECAM-1 or GST before varying concentrations (25, 50, 100, 200, 400 nM) of individual N-SH2, C-SH2 ter-
minal or NC-SH2 domains of SHP-1 and SHP-2 were £owed over the chip. GST is included as a control. For PLC-Q1 binding, individual
N-SH2, C-SH2, NC-SH2, NC-SH3 and SH3 domains were used. The presence of accessible phosphorylated GST-PECAM-1 was con¢rmed us-
ing 4G10 monoclonal antibody binding.
Fig. 2. SH2 domains of SHP-1, SHP-2, SHIP and PLC-Q1 interact speci¢cally with GST-PECAM-1 in a phosphotyrosine and dose-dependent
manner. BIAcore sensor chip was immobilised with in vitro kinase-treated GST-PECAM-1 or GST before varying concentrations (25, 50, 100,
200, 400 nM) of GST-SH2 domains from NC-SHP-1, NC-SHP-2, SHIP, NC-SH3-PLC-Q1, Shc, Grb2, N-PI-3 kinase p85, GST were £owed
over the chip. Sensorgrams were analysed as described in section 2. Binding to non-phosphorylated PECAM-1 and GST were subtracted from
the data and in all cases was less than 50 RU. Binding to in vitro kinase-treated GST was included in each case to exclude any potential inter-
action between the GST fusion tags. The presence of accessible phosphorylated GST-PECAM-1 was con¢rmed using 4G10 monoclonal anti-
body binding.
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(Fig. 4A). SHP-1, SHP-2 and PLC-Q1 all contain a pair of
tandem SH2 domains, so to map their relative binding to
PECAM-1, we examined the association of individual NC-
SH2 domains to the biotinylated phosphopeptides (Fig. 4).
N-SHP-2 interacted e⁄ciently with pY663 containing phos-
phopeptide whereas C-SHP-2 was unable to bind either phos-
phopeptide. There was very little interaction between either of
the individual SH2 domains of SHP-1 and the PECAM-1
phosphopeptides, suggesting that both SH2 domains of
SHP-1 and both tyrosine residues in PECAM-1 are required
for e⁄cient SHP-1 binding (Fig. 4A). N-PLC-Q1 bound either
phosphopeptide, with a slight preference for Y663, whereas C-
PLC-Q1 could only bind Y663 but not Y686 (Fig. 4B). A model
of how these SH2 domains interact with PECAM-1, together
with their preferred ligand binding consensus sequences,
where known, is shown in Fig. 5.
3.3. Direct interaction between tyrosine-phosphorylated cellular
PECAM-1 and SHP-1, SHP-2, SHIP and PLC-Q1
To address whether the SH2 domains of SHP-1, SHP-2,
SHIP and PLC-Q1 directly associate with PECAM-1 expressed
in a cellular context, PECAM-1 was immunoprecipitated from
pervanadate-treated THP-1 cells (which express PECAM-1 in
a basal unphosphorylated state). Far Western blots using
NC-SHP-1, NC-SHP-2, SHIP and NC-PLC-Q1 GST fusion
proteins demonstrated that these proteins bound directly
to tyrosine-phosphorylated PECAM-1 (Fig. 6). PLC-Q1 also
associated with an approximately 80^85 kDa phosphotyro-
sine containing protein, that co-immunoprecipitated with
PECAM-1 in pervanadate-treated cells. The identity of
this protein remains to be elucidated. Together, these data
provide evidence that the direct association of SHP-1, SHP-
2, SHIP and PLC-Q1 with PECAM-1 is not merely an in
Fig. 4. Interaction of PECAM-1 phosphopeptides with individual SH2 domains from SHP-1, SHP-2 and SHIP and PLC-Q1. (A) Individual N-
SH2, C-SH2 terminal or NC-SH2 domains of SHP-1 and SHP-2 and the single SH2 domain of SHIP were allowed to interact at concentra-
tions of 25, 50, 100, 200, 400 nM with the immobilised biotinylated PECAM-1 phosphopeptides NSDVQpY663TEVQV and DTETV-
pY686SEVRK. (B) Individual N-SH2, C-SH2, NC-SH2, NC-SH3 and SH3 domains from PLC-Q1 were allowed to interact at concentrations of
25, 50, 100, 200, 400 nM with the immobilised biotinylated PECAM-1 phosphopeptides NSDVQpY663TEVQV and DTETVpY686SEVRK. In
all cases, the presence of accessible phosphorylated peptides was con¢rmed using 4G10 monoclonal antibody binding. There was no binding to
biotinylated non-phosphorylated peptides (data not shown).
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vitro phenomenon, but occurs in the context of cellular acti-
vated PECAM-1.
4. Discussion
The association of PECAM-1 with SHP-1 and SHP-2 has
been previously described and shown to be mediated by the
SH2 domains of these two phosphatases [3^7]. We have ex-
tended these observations to map the dominant PECAM-1
binding sites for SHP-1 and SHP-2. Both SH2 domains of
SHP-1 are required in tandem to bind PECAM-1. Individual
phosphopeptides spanning Y663 or Y686 in PECAM-1 were
unable to support signi¢cant binding of SHP-1, suggesting
that in addition to tandem SH2 domains, tandem pY663 and
pY686 residues are also required for optimal SHP-1/PECAM-1
association. A very similar ¢nding has been observed for the
interaction of SHP-1 with CD22 where, in addition to tandem
SH2 domains, a minimum of two tyrosine residues in CD22
are required for the association with SHP-1 [14]. In contrast,
SHP-2 binds PECAM-1 using predominantly the N-SH2 do-
main, with the major binding site on PECAM-1 residing with-
in the Y663 motif, in agreement with other studies [4].
Like PECAM-1, the platelet derived growth factor (PDGF)L
receptor binds SHP-2 at residues surrounding Y1009 [15] and
shares a signi¢cant homology with the phosphotyrosine motif
surrounding Y663 in PECAM-1 (VLY1009TAVQ for the PDGFL
receptor and VQY663TEVQ for PECAM-1). The PDGFL re-
ceptor also associates with PLC-Q1 via tandem tyrosine resi-
dues Y1009 and Y1021 [16]. Although the binding site for the C-
SH2 domain of PLC-Q1 appears to reside predominantly with-
in Y1021, Y1009 also contributes to the activation of PLC-Q1 via
the NH-SH2 domain of PLC-Q1, binding the consensus motif
Y(L/I/V)(E/D)(L/I/V) [17,18]. Both VQY663TEV and
TVY686SEV in PECAM-1 closely match this consensus se-
quence, supporting our ¢ndings that N-PLC-Q1 can bind
both pY663 and pY686 containing PECAM-1 peptides equally
well (Fig. 4B).
Unlike its N-SH2 domain, the C-SH2 domain of PLC-Q1
can only bind the VQY663TEV motif. The consensus sequence
for C-PLC-Q1 binding is Y(V/I)(I/L)(P/V/I) which only weakly
conforms to the PECAM-1 sequence VQY663TEV. However,
there appears to be a con£ict between the experimentally de-
termined structural requirements for PLC-Q1 binding, using a
mutated phosphopeptide binding analysis [17,19] and func-
tional studies in whole cells. Here, additional residues other
than the three immediately following the phosphotyrosine res-
idues contribute to the association of PLC-Q1 with the PDGF
receptor [20,21].
Our ¢nding that PLC-Q1 can associate with the cytoplasmic
tail of PECAM-1 is of interest given the recent ¢ndings of
Fig. 5. Comparison of ligand binding motifs within PECAM-1 Y663 and Y686 with the predicted consensus sequences for SHP-1, SHP-2 SHIP
and PLC-Q1 SH2 domains. Amino acids within the PECAM-1 cytoplasmic domain matching any of the consensus sequences are shown in
bold. Individual SH2 domains which interact with PECAM-1 Y663TEV or Y686SEV are shown boxed. Weak interaction is shown as a hatched
box and in the case of SHP-1 where both NC-SH2 domains appear to be required for binding PECAM-1, the interacting box is shown between
the two tyrosine residues. The predicted ligand binding motifs for the individual SH2 domains, where known, are shown within the boxes.
Fig. 6. Direct interaction of tyrosine-phosphorylated cellular PE-
CAM-1 with SH2 domains from SHP-1, SHP-2 SHIP and PLC-Q1.
THP-1 cells either stimulated (+) or not (3) with pervanadate were
lysed and immunoprecipitated with anti-PECAM-1 antibody, before
SDS-PAGE analysis and blotting with either anti-phosphotyrosine
antibody, PY20, anti-PECAM-1 antibody 9G11 or GST fusion pro-
teins of NC-SHP-1, NC-SHP-2, SHIP and NC-SH3-PLC-Q1. The
positions of the Ig heavy (H) and light chain (L) are indicated as
well as a 80^85 kD protein, which associates with PLC-Q1 from
stimulated PECAM-1 immunoprecipitates. There was no binding of
GST protein.
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Gurubhagavatula et al. that ligation of PECAM-1 on endo-
thelial cells leads to an increase in the intracellular calcium
and prostacyclin release [22]. Although we have not demon-
strated that engagement of PECAM-1 leads to PLC-Q1 acti-
vation, it is tempting to speculate that this pathway may pro-
vide a molecular basis for the calcium £uxes observed in these
endothelial cells [23,24]. Experiments to test these possibilities
are currently underway.
We have also found that PECAM-1 binds the inositol-poly-
phosphate 5-phosphatase, SHIP. This SH2 containing protein
is induced to associate with the adaptor protein Shc by multi-
ple cytokines and may play a role in the negative regulation of
hemopoietic cells mediated by ITIM bearing receptors such as
FcQRIIb [25^27] and inhibitory receptors on natural killer
cells [28]. SHIP has also been shown to associate with
ITAM bearing receptors such as the high a⁄nity IgE receptor,
FcORI [25,29]. Within both ITAMs and ITIMs, SHIP displays
preferential binding to the COOH-terminal phosphotyrosine
[25,28], a ¢nding that we have also observed for PECAM-1
(Fig. 4A). Like PECAM-1, SHIP is present in human platelets
and has recently been implicated in platelet integrin activation
[30]. Furthermore, SHIP and PECAM-1 both become redis-
tributed to the cytoskeleton upon platelet activation and ag-
gregation [30,31]. It is therefore possible that PECAM-1/SHIP
interactions might play a role in the integrin-mediated adhe-
sion and cytoskeletal rearrangement during platelet activation.
Newman has recently suggested that PECAM-1 is predom-
inantly an ITIM bearing receptor, based on its ability to bind
SHP-1 and SHP-2, the genomic organisation of its cytoplas-
mic domain and widely spaced phosphotyrosine residues [32].
However, our results suggest that PECAM-1 can also func-
tion as an ITAM bearing receptor based on the following
observations. Firstly, there is strong homology of the amino
acid residues surrounding PECAM-1 Y663 and Y686 to the
consensus ITAM sequence [9,33] (Fig. 7). Secondly, the tyro-
sine residues in ITAMs are encoded by two di¡erent exons
with the ¢rst aspartate/glutamate inconsistently being the
product of yet another exon [34]. In PECAM-1, exons 12,
13 and 14 encode the ¢rst aspartate, the second aspartate
and Y663 and Y686, respectively [2]. Thirdly, the cytoplasmic
domain of PECAM-1 is phosphorylated by c-Src and associ-
ates with PLC-Q1 (a classical ITAM binding signalling pro-
tein) and SHIP (which has been shown to associate with both
ITIM and ITAM motifs) [25,28]. The spacing between the two
phosphotyrosine residues in PECAM-1 (22 amino acids),
while not conforming to the short spacing in ITAMs (typically
10^15 amino acids), is not as wide as many other Ig-ITIMs
(typically greater than 25 amino acids) [35]. Our results there-
fore suggest that PECAM-1 may act as both an ITAM as well
as an ITIM bearing receptor. How the association of di¡erent
cytoplasmic signalling proteins with PECAM-1 is regulated
and the di¡erential consequences of these interactions in
blood, vascular and epithelial cells, represents an important
area for future research.
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